Biomarkers such as programmed cell death ligand 1 (PD-L1), tumor mutational burden (TMB) and microsatellite instability high (MSI-H)/mismatch repair deficiency (dMMR) have been shown to be predictors of ICIs antitumor efficacy (28–31). The gene discussed is CD274; the disease is neoplasm.